Adjuvant Chemotherapy in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-04-12

AUTHORS

John P. Neoptolemos , David Cunningham , Francesco Sclafani , Paula Ghaneh

ABSTRACT

Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting. More... »

PAGES

1039-1071

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4939-7193-0_43

DOI

http://dx.doi.org/10.1007/978-1-4939-7193-0_43

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103221261


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7700.0", 
          "name": [
            "Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sclafani", 
        "givenName": "Francesco", 
        "id": "sg:person.0653217174.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Department of Surgery, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK", 
            "Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-04-12", 
    "datePublishedReg": "2018-04-12", 
    "description": "Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10\u201315% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.", 
    "editor": [
      {
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "type": "Person"
      }, 
      {
        "familyName": "Urrutia", 
        "givenName": "Raul", 
        "type": "Person"
      }, 
      {
        "familyName": "Abbruzzese", 
        "givenName": "James L.", 
        "type": "Person"
      }, 
      {
        "familyName": "B\u00fcchler", 
        "givenName": "Markus W.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4939-7193-0_43", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4939-7191-6", 
        "978-1-4939-7193-0"
      ], 
      "name": "Pancreatic Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "pancreatic cancer", 
      "survival advantage", 
      "combination therapy", 
      "ESPAC-1 trial", 
      "single-agent gemcitabine", 
      "CONKO-001 study", 
      "ESPAC-3 trial", 
      "JASPAC 01 trial", 
      "ESPAC-4 trial", 
      "combination chemotherapy regimens", 
      "large randomized trials", 
      "adjuvant combination chemotherapy", 
      "phase III study", 
      "level 1 evidence", 
      "better toxicity profile", 
      "clear survival advantage", 
      "curative surgery", 
      "adjuvant setting", 
      "adjuvant chemoradiation", 
      "combination chemoradiation", 
      "GITSG study", 
      "chemoradiation regimen", 
      "ESPAC-1", 
      "adjuvant chemotherapy", 
      "advanced disease", 
      "adjuvant therapy", 
      "adjuvant regimens", 
      "chemotherapy regimens", 
      "most patients", 
      "III study", 
      "randomized study", 
      "combination chemotherapy", 
      "randomized trials", 
      "systemic disease", 
      "poor prognosis", 
      "Western patients", 
      "treatment options", 
      "cancer death", 
      "folinic acid", 
      "survival differences", 
      "chemoradiation", 
      "toxicity profile", 
      "chemotherapy", 
      "gemcitabine", 
      "combination studies", 
      "patients", 
      "major cause", 
      "therapy", 
      "trials", 
      "cancer", 
      "Japanese population", 
      "capecitabine", 
      "resection", 
      "regimen", 
      "regimens", 
      "surgery", 
      "disease", 
      "EORTC", 
      "recurrence", 
      "prognosis", 
      "follow", 
      "study", 
      "setting", 
      "death", 
      "survival", 
      "intervention", 
      "cause", 
      "options", 
      "population", 
      "FA", 
      "evidence", 
      "differences", 
      "results", 
      "contrast", 
      "acid", 
      "profile", 
      "use", 
      "S1", 
      "number", 
      "advantages", 
      "observations", 
      "superiority", 
      "justification"
    ], 
    "name": "Adjuvant Chemotherapy in Pancreatic Cancer", 
    "pagination": "1039-1071", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103221261"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4939-7193-0_43"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4939-7193-0_43", 
      "https://app.dimensions.ai/details/publication/pub.1103221261"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_205.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4939-7193-0_43"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7193-0_43'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7193-0_43'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7193-0_43'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-7193-0_43'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      107 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4939-7193-0_43 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N8a9ecf6f6d2c45878220c741790d1639
4 schema:datePublished 2018-04-12
5 schema:datePublishedReg 2018-04-12
6 schema:description Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.
7 schema:editor Nce19482d39a644418d18c6f2be2ccdf0
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N3e35d1ea8c6947f78a679dda550adb32
11 schema:keywords CONKO-001 study
12 EORTC
13 ESPAC-1
14 ESPAC-1 trial
15 ESPAC-3 trial
16 ESPAC-4 trial
17 FA
18 GITSG study
19 III study
20 JASPAC 01 trial
21 Japanese population
22 S1
23 Western patients
24 acid
25 adjuvant chemoradiation
26 adjuvant chemotherapy
27 adjuvant combination chemotherapy
28 adjuvant regimens
29 adjuvant setting
30 adjuvant therapy
31 advanced disease
32 advantages
33 better toxicity profile
34 cancer
35 cancer death
36 capecitabine
37 cause
38 chemoradiation
39 chemoradiation regimen
40 chemotherapy
41 chemotherapy regimens
42 clear survival advantage
43 combination chemoradiation
44 combination chemotherapy
45 combination chemotherapy regimens
46 combination studies
47 combination therapy
48 contrast
49 curative surgery
50 death
51 differences
52 disease
53 evidence
54 folinic acid
55 follow
56 gemcitabine
57 intervention
58 justification
59 large randomized trials
60 level 1 evidence
61 major cause
62 most patients
63 number
64 observations
65 options
66 pancreatic cancer
67 patients
68 phase III study
69 poor prognosis
70 population
71 profile
72 prognosis
73 randomized study
74 randomized trials
75 recurrence
76 regimen
77 regimens
78 resection
79 results
80 setting
81 single-agent gemcitabine
82 study
83 superiority
84 surgery
85 survival
86 survival advantage
87 survival differences
88 systemic disease
89 therapy
90 toxicity profile
91 treatment options
92 trials
93 use
94 schema:name Adjuvant Chemotherapy in Pancreatic Cancer
95 schema:pagination 1039-1071
96 schema:productId N044d8d12980d48b88307c419d1b40d8f
97 Nec63d2db1cc5433cb497f169eddb2b92
98 schema:publisher N74ea023adede40b2bbfa1273838a1a27
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103221261
100 https://doi.org/10.1007/978-1-4939-7193-0_43
101 schema:sdDatePublished 2022-10-01T06:54
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Nad2a7740bfa549dcb4d6464ba8b817f0
104 schema:url https://doi.org/10.1007/978-1-4939-7193-0_43
105 sgo:license sg:explorer/license/
106 sgo:sdDataset chapters
107 rdf:type schema:Chapter
108 N044d8d12980d48b88307c419d1b40d8f schema:name doi
109 schema:value 10.1007/978-1-4939-7193-0_43
110 rdf:type schema:PropertyValue
111 N2720881822ae4a099b79216344f713d2 rdf:first sg:person.01320161130.16
112 rdf:rest Nfbe1890343d9466aa6f136090281e3e7
113 N3e35d1ea8c6947f78a679dda550adb32 schema:isbn 978-1-4939-7191-6
114 978-1-4939-7193-0
115 schema:name Pancreatic Cancer
116 rdf:type schema:Book
117 N4abef66687064557b46c5b185e482eb9 rdf:first N77bfd81344204a4d90295dd849ce69e3
118 rdf:rest rdf:nil
119 N55c21684f6c34029962c29bc10eddf82 schema:familyName Neoptolemos
120 schema:givenName John P.
121 rdf:type schema:Person
122 N6862b29a9ce746ebb1e1adcefa4c759f rdf:first Nea6d91206220424e95059d06becdb2a7
123 rdf:rest N4abef66687064557b46c5b185e482eb9
124 N74ea023adede40b2bbfa1273838a1a27 schema:name Springer Nature
125 rdf:type schema:Organisation
126 N77bfd81344204a4d90295dd849ce69e3 schema:familyName Büchler
127 schema:givenName Markus W.
128 rdf:type schema:Person
129 N8a9ecf6f6d2c45878220c741790d1639 rdf:first sg:person.0750565077.18
130 rdf:rest N2720881822ae4a099b79216344f713d2
131 Nad2a7740bfa549dcb4d6464ba8b817f0 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Nccd27be96c0b49c5ad7c205ccfa0dae7 rdf:first Nda1a2afcedbe4edcb67b93f6257ae40b
134 rdf:rest N6862b29a9ce746ebb1e1adcefa4c759f
135 Nce19482d39a644418d18c6f2be2ccdf0 rdf:first N55c21684f6c34029962c29bc10eddf82
136 rdf:rest Nccd27be96c0b49c5ad7c205ccfa0dae7
137 Nda1a2afcedbe4edcb67b93f6257ae40b schema:familyName Urrutia
138 schema:givenName Raul
139 rdf:type schema:Person
140 Ne1dc9298466b417a9e95032070f8f006 rdf:first sg:person.07372440237.86
141 rdf:rest rdf:nil
142 Nea6d91206220424e95059d06becdb2a7 schema:familyName Abbruzzese
143 schema:givenName James L.
144 rdf:type schema:Person
145 Nec63d2db1cc5433cb497f169eddb2b92 schema:name dimensions_id
146 schema:value pub.1103221261
147 rdf:type schema:PropertyValue
148 Nfbe1890343d9466aa6f136090281e3e7 rdf:first sg:person.0653217174.51
149 rdf:rest Ne1dc9298466b417a9e95032070f8f006
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
154 schema:name Oncology and Carcinogenesis
155 rdf:type schema:DefinedTerm
156 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.5072.0
157 schema:familyName Cunningham
158 schema:givenName David
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
160 rdf:type schema:Person
161 sg:person.0653217174.51 schema:affiliation grid-institutes:grid.5072.0
162 schema:familyName Sclafani
163 schema:givenName Francesco
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51
165 rdf:type schema:Person
166 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.10025.36
167 schema:familyName Ghaneh
168 schema:givenName Paula
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
170 rdf:type schema:Person
171 sg:person.0750565077.18 schema:affiliation grid-institutes:grid.7700.0
172 schema:familyName Neoptolemos
173 schema:givenName John P.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
175 rdf:type schema:Person
176 grid-institutes:grid.10025.36 schema:alternateName Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
177 schema:name Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
178 Department of Surgery, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
179 rdf:type schema:Organization
180 grid-institutes:grid.5072.0 schema:alternateName Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK
181 schema:name Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK
182 rdf:type schema:Organization
183 grid-institutes:grid.7700.0 schema:alternateName Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
184 schema:name Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...